Clinical Trials Directory

Trials / Unknown

UnknownNCT04029441

The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology

he Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology

Status
Unknown
Phase
Study type
Observational
Enrollment
1,200 (estimated)
Sponsor
Shandong University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Subjects who are included will recieve Hp eradication therapy based on antimicrobial susceptibility test. After the therapy, the subjects will be divided into two groups, the successful group and the failure group. And then they wiil be followed up to observe the development of the gastric mucosa pathology.

Detailed description

Subjects who are included will recieve Hp eradication therapy based on antimicrobial susceptibility test. After the therapy, the subjects will be divided into two groups, the successful group and the failure group. The subjects who fail to eradicate the Hp after initial treatment and rescue treatment will go into the failure group. Otherwhile, they will go to the successful group.And then they wiil be followed up to observe the development of the gastric mucosa pathology. For mild atrophy gastritis, non- intestinal metaplasial gastritis, follow-up is performed every 2-3 years.For severe atrophy gastritis, intestinal metaplasial gastritis, follow-up is performed every 1-2 years. For patients wth high-grade intraepithelial neoplasia, they can be included 3 months after the endoscopic treatment, and the follow up will be performed at 6, 12 months after the treatment and then the follow up will be carried out every 1 year. For non-atrophic gastritis, no follow-up will be performed. All included patients will recieve a follow-up at the endpoint of 5 years. The follow-up includes endoscopy examination and serum test of PG I,PG II and gastrin 17.

Conditions

Interventions

TypeNameDescription
OTHERthe eradication Hpthe eradication of Hp based on antimicrobial susceptibility test

Timeline

Start date
2018-09-01
Primary completion
2021-09-30
Completion
2021-09-30
First posted
2019-07-23
Last updated
2019-07-23

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04029441. Inclusion in this directory is not an endorsement.